Technical Analysis for INSM - Insmed, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| 200 DMA Resistance | Bearish | -2.04% | |
| 20 DMA Support | Bullish | -2.04% | |
| Down 3 Days in a Row | Weakness | -2.04% | |
| 200 DMA Resistance | Bearish | -3.48% | |
| 20 DMA Support | Bullish | -3.48% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 10 hours ago |
| Down 1% | about 10 hours ago |
| Possible Inside Day | about 10 hours ago |
| Fell Below 20 DMA | about 10 hours ago |
| Gap Up Closed | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
Insmed, Inc. Description
Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing targeted inhalation therapies for patients battling serious lung diseases. Its lead candidate ARIKACE is engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the treatment for two identified patient populations comprising cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). The company's Phase III registrational study of ARIKACE in CF patients in Europe and Canada has completed enrollment; and Phase II clinical trial in NTM patients is under way with clinical results. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Infectious Diseases Cystic Fibrosis Microbiology Bacterial Disease Pseudomonas Tuberculosis Bacteriology Lung Diseases Lung Infection Nontuberculous Mycobacteria Lung Infections Mycobacterium
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 32.0 |
| 52 Week Low | 18.31 |
| Average Volume | 1,771,501 |
| 200-Day Moving Average | 26.15 |
| 50-Day Moving Average | 26.40 |
| 20-Day Moving Average | 25.36 |
| 10-Day Moving Average | 25.78 |
| Average True Range | 1.17 |
| RSI (14) | 40.83 |
| ADX | 20.7 |
| +DI | 20.07 |
| -DI | 14.68 |
| Chandelier Exit (Long, 3 ATRs) | 24.81 |
| Chandelier Exit (Short, 3 ATRs) | 27.03 |
| Upper Bollinger Bands | 26.58 |
| Lower Bollinger Band | 24.13 |
| Percent B (%b) | 0.33 |
| BandWidth | 9.66 |
| MACD Line | -0.24 |
| MACD Signal Line | -0.28 |
| MACD Histogram | 0.0431 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 26.87 | ||||
| Resistance 3 (R3) | 27.07 | 26.63 | 26.54 | ||
| Resistance 2 (R2) | 26.63 | 26.14 | 26.53 | 26.43 | |
| Resistance 1 (R1) | 25.78 | 25.83 | 25.56 | 25.58 | 26.33 |
| Pivot Point | 25.34 | 25.34 | 25.23 | 25.24 | 25.34 |
| Support 1 (S1) | 24.49 | 24.85 | 24.27 | 24.29 | 23.53 |
| Support 2 (S2) | 24.05 | 24.54 | 23.95 | 23.43 | |
| Support 3 (S3) | 23.20 | 24.05 | 23.32 | ||
| Support 4 (S4) | 23.00 |
